Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CYP2C8 and CYP3A Modulators on Ozanimod PK
NCT03624959Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC) (5 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration up to 14 days, Area Under the Curve to Infinity up to 14 days and 1 more. Started Jun 2018; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03624959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624959.